When people start looking into growth hormone (GH) peptides, two names come up almost immediately: CJC-1295 and Ipamorelin. Both are designed to increase the body’s natural release of growth hormone, but they do it in very different ways.
That difference is why researchers often pair them together instead of choosing one over the other. Know how each peptide works, what makes them different, what research currently shows, and why the CJC-1295 + Ipamorelin stack has become one of the most talked-about combinations in peptide research.
What Is CJC-1295?
CJC-1295 is a synthetic version of GHRH (growth hormone-releasing hormone), which is the hormone your hypothalamus naturally uses to signal the pituitary gland to release growth hormone.
The peptide was originally developed by ConjuChem Biotechnologies and contains 29 amino acids, modified to resist breakdown in the body. One thing that makes CJC-1295 unique is that it exists in two separate forms.
| CJC-1295 with DAC (Drug Affinity Complex) | CJC-1295 without DAC (Mod GRF 1-29) |
|---|---|
|
The DAC version includes a Drug Affinity Complex that allows the peptide to bind to albumin in the bloodstream. That dramatically extends its half-life to around 6–8 days. Instead of producing short GH spikes, this version creates a more sustained elevation in growth hormone and IGF-1 levels over time. |
Without DAC, the peptide has a much shorter half-life, roughly 30 minutes. You’ll see this version referred to as Mod GRF 1-29 or “CJC-1295 no DAC.” Because it clears much faster, it produces more natural GH pulses. That shorter action window is one reason many researchers prefer pairing it with Ipamorelin. |
Quick Facts:
- 29 amino acids
- 6–8 day half-life (with DAC)
- ~30 minute half-life (without DAC)
What Is Ipamorelin?
Ipamorelin is a GHRP (growth hormone-releasing peptide). Instead of acting like GHRH, it mimics ghrelin, the hormone commonly associated with hunger and GH release. Unlike older GHRPs such as GHRP-6 or GHRP-2, Ipamorelin was designed to be far more selective.
That selectivity matters because earlier GHRPs often increased cortisol, prolactin, and aldosterone levels alongside growth hormone. Ipamorelin, on the other hand, primarily targets GH release while having much less impact on those other hormones.
It’s also a much smaller peptide, containing only 5 amino acids.
Quick Facts
- 5 amino acids
- ~2 hour half-life
- Highly selective GH release
The Biggest Difference Between Them
The easiest way to think about these two peptides is this:
- CJC-1295 works upstream by mimicking GHRH signalling from the hypothalamus.
- Ipamorelin works directly on the pituitary by activating the ghrelin receptor.
Even though both increase GH output, they do it through separate receptor pathways. That’s the entire reason stacking them together became so popular in research settings.
How CJC-1295 Works
CJC-1295 binds to GHRH receptors located on pituitary somatotroph cells. These are the cells responsible for producing and releasing growth hormone. Once activated, those receptors trigger intracellular signalling that increases both GH synthesis and GH release.
The DAC version keeps that signal active for much longer, which is why IGF-1 levels can stay elevated for days after administration. In simpler terms, CJC-1295 extends and amplifies the body’s normal GH signalling process.
How Ipamorelin Works
Ipamorelin acts through a distinct receptor, GHS-R1a, also known as the ghrelin receptor. Once activated, the receptor triggers a rapid pulse of GH release that more closely resembles the body’s natural secretion rhythm.
One of Ipamorelin’s biggest advantages is its apparent selectivity for GH release. Research consistently shows minimal increases in cortisol or prolactin compared to older GH secretagogues. That “cleaner” profile is a major reason it became so widely used.
CJC-1295 vs Ipamorelin: Side-by-Side Comparison
| Factor | CJC-1295 (DAC) | CJC-1295 (No DAC) | Ipamorelin |
|---|---|---|---|
|
Peptide Type |
GHRH analog |
GHRH analog |
GHRP / ghrelin mimetic |
|
Half-Life |
6–8 days |
~30 minutes |
~2 hours |
|
GH Pattern |
Sustained elevation |
Pulsatile |
Pulsatile |
|
Dosing Frequency |
1–2x weekly |
2–3x daily |
2–3x daily |
|
Cortisol Impact |
Minimal |
Minimal |
Minimal |
|
Prolactin Impact |
Minimal |
Minimal |
Minimal |
|
Hunger Increase |
None |
None |
Usually mild |
|
Main Research Focus |
Long-term GH/IGF-1 elevation |
Natural GH pulses |
Selective GH release |
Understanding the GH Release Patterns
This is where the differences become more noticeable.
CJC-1295 with DAC
This version creates a slower, more sustained increase in GH and IGF-1. Some research found that IGF-1 levels remained elevated for up to 2 weeks after a single administration. Instead of distinct spikes, the body experiences a more continuous GH signal.
CJC-1295 without DAC
The no-DAC version behaves much differently. Because the half-life is so short, each dose creates a temporary GH pulse that returns to baseline relatively quickly. Many researchers prefer this because it more closely mimics natural GH secretion.
Ipamorelin
Ipamorelin also creates pulsatile GH release, but through the ghrelin pathway. GH levels typically rise quickly after administration, peak around 30–40 minutes later, and then gradually return to baseline over the next few hours.
What Research Says About CJC-1295
Both clinical and preclinical studies have explored CJC-1295, particularly the DAC version.
Some commonly reported findings include:
- IGF-1 increases of 1.5–3x baseline
- Elevated IGF-1 lasting 6–14 days
- GH increases ranging from 2–10 fold
- Possible improvements in lean mass and fat reduction trends
- Mostly mild side effects like flushing or injection site irritation
It’s important to note that clinical development of CJC-1295 with DAC was discontinued after a participant’s death during a trial, although researchers never definitively linked the event to the peptide itself. Research still continues in non-clinical settings.
What Research Says About Ipamorelin
Ipamorelin has been studied for several different applications, including GH release and post-surgical recovery.
Some of the most consistent findings include:
- Strong dose-dependent GH release
- Minimal cortisol elevation
- Minimal prolactin elevation
- Better selectivity compared to GHRP-2 and GHRP-6
- Generally, mild side effects in studies
Its selective profile is one of the main reasons it became so popular compared to earlier GHRPs.
Why Researchers Stack CJC-1295 + Ipamorelin
This combination became popular because the two peptides activate distinct GH pathways simultaneously.
Research on combining GHRH analogs with GHRPs consistently shows a synergistic effect. In other words, the GH response from the combination is greater than what either peptide produces alone.
That synergy is the main scientific rationale behind the stack.
Why the Stack Is So Popular
| Synergistic GH Release | Cleaner Hormonal Profile |
|---|---|
|
Activating both receptor systems simultaneously tends to produce a stronger GH response. |
Unlike older GHRPs, Ipamorelin generally does not heavily increase cortisol or prolactin. |
| More Natural GH Pulses | Convenient Pairing |
|---|---|
|
Using CJC-1295 without DAC helps preserve a pulsatile GH rhythm instead of maintaining constant elevation. |
The shorter half-lives of Ipamorelin and CJC-1295 no DAC work well together for co-administration. |
Typical Research Dosing Protocol
In research settings, CJC-1295 without DAC and Ipamorelin are commonly administered together 2–3 times daily.
Typical timing often includes:
- Morning
- Post-workout
- Before bed
These time points are usually chosen because they align with natural GH secretion patterns.
| Parameter | CJC-1295 (No DAC) | Ipamorelin |
|---|---|---|
|
Typical Research Dose |
100–300 mcg |
100–300 mcg |
|
Frequency |
2–3x daily |
2–3x daily |
|
Timing |
Morning, post-workout, bedtime |
Same |
|
Typical Duration |
8–12 weeks |
8–12 weeks |
️ ⚠ These figures come from research settings only. Neither peptide is approved for therapeutic human use, and responses can vary significantly between individuals.
Which One Makes More Sense?
The answer depends entirely on the research goal.
CJC-1295 with DAC May Make More Sense If:
- Sustained GH or IGF-1 elevation is the priority
- Less frequent dosing is preferred
- Long-term GH exposure is being studied
CJC-1295 without DAC May Be Better If:
- Preserving natural GH pulsatility matters
- Timing control is important
- The peptide will be combined with Ipamorelin
Ipamorelin May Be Preferred If:
- Selective GH release is the goal
- Avoiding cortisol or prolactin increases is important
- Ghrelin-mediated GH release is being studied
The Stack Often Makes Sense If:
- Maximum GH release is the objective
- Researchers want synergistic signalling
- The focus involves recovery, body composition, or regenerative applications
Muscle Growth and Recovery Research
A major reason these peptides receive so much attention is their relationship to growth hormone and IGF-1 production.
GH plays an important role in:
- Protein synthesis
- Nitrogen retention
- Recovery
- Lean mass development
Compared with some older GH secretagogues, the CJC-1295 + Ipamorelin combination is often viewed as a more balanced option due to its cleaner side-effect profile.
Researchers also commonly compare these peptides with compounds like:
- Sermorelin
- Hexarelin
- MK-677
MK-677 is especially notable because it’s oral rather than injectable, although it works differently and has a much longer duration of action.
Reconstitution and Storage Basics
Both peptides are usually sold as lyophilized (freeze-dried) powders that need to be reconstituted before use.
|
Before Reconstitution |
|
|
Reconstitution |
|
|
After Reconstitution |
|
Possible Side Effects
Both peptides appear relatively well tolerated in research, but side effects can still happen.
CJC-1295 Side Effects
- Injection site irritation
- Flushing
- Headache
- Dizziness
- Water retention
Ipamorelin Side Effects
- Injection site irritation
- Mild headache
- Slight hunger increase
- Temporary tiredness or lethargy
Long-term safety data are still limited for both compounds. As with any GH-elevating peptide, researchers continue monitoring potential concerns related to glucose metabolism, fluid retention, insulin sensitivity, and cell proliferation signalling.
Contraindications and Cautions
These peptides are generally avoided in cases involving:
- Active cancer
- Certain cancer histories
- Diabetic retinopathy
- Pregnancy or breastfeeding
- Severe liver or kidney impairment
- Known hypersensitivity to peptide compounds
CJC-1295 vs Ipamorelin: Which GH Peptide Works Better?
While both CJC-1295 and Ipamorelin stimulate growth hormone release, they approach the process from completely different angles. CJC-1295 works through GHRH signalling to extend GH release, while Ipamorelin stimulates selective GH pulses through the ghrelin receptor pathway.
When combined, the two peptides create a synergistic effect that has made the CJC-1295 + Ipamorelin stack one of the most widely researched GH peptide combinations today. Like all research peptides, Proper sourcing, handling, and professional oversight remain essential in any setting.
Frequently Asked Questions
Why is bedtime dosing common with GH peptides?
Natural growth hormone release peaks during deep sleep, particularly during slow-wave sleep cycles. Researchers often schedule peptides such as CJC-1295 (no DAC) and Ipamorelin before bedtime to align administration with the body’s normal nocturnal GH rhythm. The idea is that timing peptide-induced GH pulses near natural secretion windows may help preserve physiological signalling patterns.
Why are injection timing and meal timing often separated?
Growth hormone release can be influenced by blood glucose and insulin levels. High carbohydrate intake may temporarily blunt GH secretion. Because of that, many research protocols separate peptide administration from large meals, especially carbohydrate-heavy meals, to avoid interfering with GH pulse amplitude.
Is there a reason GH peptides are often administered subcutaneously instead of intramuscularly?
Subcutaneous administration generally provides slower absorption and more stable release characteristics for many peptides. It’s also less invasive and often easier to standardize in research settings. Intramuscular delivery may alter absorption kinetics depending on blood flow and tissue depth.
